Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability
Authors:
- Huynh CaoHCHuynh Cao
- Verena TadrosVTVerena Tadros
- Benjamin HiramotoBHBenjamin Hiramoto
- Kevin LeeperKLKevin Leeper
- Christopher HinoCHChristopher Hino
- Jeffrey XiaoJXJeffrey Xiao
- Bryan PhamBPBryan Pham
- Do Hyun KimDKDo Hyun Kim
- Mark E. ReevesMRMark E. Reeves
- Chien-Shing ChenCCChien-Shing Chen
- Jiang F. ZhongJZJiang F. Zhong
- Ke K. ZhangKZKe K. Zhang
Open Access
- 30 April 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (5) , 1038
Abstract
Disease relapse is a common cause of treatment failure in FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic cells (blasts) with FLT3 mutations after gilteritinib (GILT, a 2nd generation tyrosine kinase inhibitor (TKI)) treatment, we performed proteomic screening of cytokine release and in vitro/ex vivo studies to investigate their associated signaling pathways and transcriptional regulation. Here, we report that macrophage migration inhibition factor (MIF) was significantly increased in the supernatant of GILT-treated blasts when compared to untreated controls. Additionally, the GILT-treated blasts that survived were found to exhibit higher expressions of the CXCR2 gene and protein, a common receptor for MIF and pro-inflammatory cytokines. The supplementation of exogenous MIF to GILT-treated blasts revealed a group of CD44High+ cells that might be responsible for the relapse. Furthermore, we identified the highly activated non-classical NFKB2 pathway after GILT-treatment. The siRNA transient knockdown of NFKB2 significantly reduced the gene expressions of MIF, CXCR2, and CXCL5. Finally, treatments of AML patient samples ex vivo demonstrated that the combination of a pharmaceutical inhibitor of the NFKB family and GILT can effectively suppress primary blasts’ secretion of tumor-promoting cytokines, such as CXCL1/5/8. In summary, we provide the first evidence that targeting treatment-activated compensatory pathways, such as the NFKB2-MIF/CXCLs-CXCR2 axis could be a novel therapeutic strategy to overcome TKI-resistance and effectively treat AML patients with FLT3 mutations.Keywords
Funding Information
- Loma Linda University GRASP
- Loma Linda University Research Innovation Grant
This publication has 53 references indexed in Scilit:
- Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory RootsClinical Cancer Research, 2011
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- The protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cellsBritish Journal of Haematology, 2009
- Role of MIF in Inflammation and TumorigenesisOncology, 2008
- Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapyBreast Cancer Research, 2008
- NF-κB and cancer — identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- CXCR1 and CXCR2 Activation and RegulationJournal of Biological Chemistry, 2007
- Biological robustnessNature Reviews Genetics, 2004
- Identification of the haematopoietic stem cell niche and control of the niche sizeNature, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003